InspireMD (NSPR)
NASDAQ:NSPR
Want to see NSPR full AI Analyst Report?
NSPR Stock Chart & Stats
$1.84
$0.06(2.18%)
At close: 4:00 PM EST
$1.84
$0.06(2.18%)
Day’s Range― - ―
52-Week Range$0.69 - $2.93
Previous CloseN/A
Volume8.46K
Average Volume (3M)102.59K
Market Cap
$33.26M
Enterprise Value$26.31M
Total Cash (Recent Filing)$41.57M
Total Debt (Recent Filing)$3.11M
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Aug 11, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding46,838,963
10 Day Avg. Volume68,719
30 Day Avg. Volume102,589
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit8.64
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$3.67Price Target Upside99.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.74
Revenue Forecast (FY)$12.49M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthQ1 revenue growth (+122% YoY) alongside accelerating U.S. sequential sales and rising international demand indicates durable commercial traction and expanding adoption. This trend supports scaling revenue over months as distribution and physician familiarity increase beyond a small base.
Strong Clinical EvidenceRobust pivotal trial outcomes materially strengthen regulatory and reimbursement prospects and provide a lasting competitive advantage. Clear safety/efficacy data improve hospital and physician adoption odds and underpin broader TCAR market access if FDA approvals follow.
Low Leverage & Manufacturing ReadinessA light debt burden preserves financial flexibility and reduces bankruptcy risk while management reports manufacturing capacity ready to support a relaunch. This combination allows the company to scale commercial supply quickly post‑regulatory clearance without heavy fixed‑cost leverage.
Bears Say
High Cash BurnPersistent, large negative operating and free cash flow materially shortens runway and forces continued reliance on equity financings or ATM programs. Recurrent burn increases dilution and execution risk unless revenue growth meaningfully outpaces OpEx over the coming quarters.
U.S. Recall And Commercial PauseThe pause halts U.S. revenue from a critical market and creates uncertain timing for return to full commercialization. Prolonged regulatory or remediation timelines can structurally delay scaling in the U.S., cede share to competitors, and dampen adoption momentum.
Large Structural LossesOperating losses far exceed current revenue, indicating the cost base is well ahead of scale. Continued wide losses erode equity, raise refinancing needs and heighten dilution risk, making profitability contingent on sustained, sizable revenue gains and margin improvement.
InspireMD News
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $0.69 and its highest was $2.93 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $33.26M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Aug 11, 2026 which is in 53 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on May 04, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.02.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.2.
How many shares outstanding does InspireMD have?
InspireMD has 46,838,963 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -5.983%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InspireMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.67 (99.28% Upside)
$3.67 (99.28% Upside)
Insider Transactions
Bought Shares
Worth $176.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.82%
12-Months-Change
Fundamentals
Return on Equity
-81.52%
Trailing 12-Months
Asset Growth
46.03%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
NSPR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong commercial traction and substantial year-over-year revenue growth (122%), expanding international sales (48% YoY), a large clinical installed base (>70,000 cases), and clear regulatory/clinical pathways (C-GUARDIANS III initiation, expected approvals). Offsetting these positives is a material near-term operational setback — a voluntary U.S. pause/recall of the CGuard Prime 135 delivery system — which led to impairment charges, planned reserves (~$1.35M combined), withdrawal of 2026 revenue guidance, increased operating expenses, and reduced cash versus year-end. Management characterizes the issue as technical (not implant safety), has identified root causes, and expects a path to remediation and relaunch, but timing is uncertain. Overall, the call balances strong growth and long-term opportunity with a meaningful short-term commercial disruption and financial impact.View all NSPR earnings summariesNSPR Stock 12 Month Forecast
Average Price Target
$3.67
▲(99.28% Upside)
Technical Analysis
Ownership Overview
21.29% Insiders
0.04% Mutual Funds
36.98% Other Institutional Investors
41.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---